Israel-based Arineta Cardiac Imaging announces U.S. FDA 510(k) clearance of the SpotLight and SpotLight Duo line of cardiovascular CT (CCT) scanners. The SpotLight Duo system enhances thoracic clinical capabilities for lung cancer, COVID-19, and pulmonary diseases while also providing extended coverage for peripheral vascular and runoff studies.
“Arineta has been the leader in cardiovascular CT technology, and the new SpotLight systems continue Arineta’s history of clinical innovation,” says Scott Schubert, Arineta CEO. “Our vision is to grow cardiac CT as the front-line non-invasive test for diagnosing, therapy planning and monitoring of cardiovascular disease—the No.1 cause of death and costs for healthcare worldwide.”
Chaim Lotan, MD, a professor at Hadassah-Hebrew University in Jerusalem, adds, “Recent guidelines from the ACC and AHA recommend cardiac CT for diagnosing chest pain, which is a significant health concern.”
The SpotLight system is a dedicated CCT system with a 25 cm field of view, offering advanced specifications for temporal and spatial resolution, whole-heart coverage, and image quality. SpotLight Duo is the next generation of Arineta CT technology, providing high-resolution scanning for cardiothoracic clinical applications. Both systems include workflow improvements for increased patient throughput.
During the Society of Cardiovascular CT conference, Arineta users discussed “Cardiac CT in an office/outpatient setting” and Arineta’s efforts to make CCT more accessible in point-of-care settings. Arineta also showcased its Mobile CCT system, which expands access to underserved populations in various healthcare settings.
ArinetaSpotLight and SpotLight Duo systems will be available for purchase and service directly through Arineta.
